In response to travel restrictions imposed during the COVID-19 pandemic, the U.S. Food and Drug Administration (“FDA”) began conducting remote regulatory assessments (“RRAs”) of medical products companies and other...more
7/7/2025
/ Executive Orders ,
Final Guidance ,
Food and Drug Administration (FDA) ,
Imports ,
Manufacturers ,
Manufacturing Facilities ,
New Guidance ,
New Regulations ,
Pharmaceutical Industry ,
Regulatory Oversight ,
Regulatory Requirements ,
Risk Assessment